Business · 02/10/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for DRAXXIN Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for DRAXXIN, a patent extension application submitted to the Department of Commerce, and is publishing this notice as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →